For Q1 FY2026 ended March 31, 2026, IDEAYA Biosciences reported revenue of $6.56 million, a net loss of $98.54 million (widening 36.5% YoY), and an operating loss of $108.54 million (widening 28.6% YoY). Diluted EPS was -$1.11 (worsening 35.4% YoY). The company held $157.5 million in cash and $937.3 million in equity, with no long-term debt.
•Revenue of $6.56 million in Q1 FY2026.
•Net loss of $98.54 million, up 36.5% year-over-year.
•Operating loss of $108.54 million, up 28.6% year-over-year.
•Cash and cash equivalents of $157.5 million as of March 31, 2026.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
IDEAYA Biosciences, Inc., a precision medicine oncology company develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas.
Its portfolio also includes IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC, IDE161, a poly ADP-ribose glycohydrolase inhibitor, IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD, IDE397, a MAT2A inhibitor for MTAP-deleted tumors, IDE892, a PRMT5 inhibitor, IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers, and IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial.
Additionally, it offers preclinical research programs focused on pharmacological inhibition. Its portfolio also includes DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery, and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform.
The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate
Clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. Incorporated in 2015, IDEAYA Biosciences is headquartered in South San Francisco, California.
IDEAYA Biosciences, Inc. is a precision medicine oncology company based in the United States. It focuses on developing targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidate is Darovasertib, an oral, potent, and selective protein kinase C (PKC) inhibitor being evaluated for uveal melanoma and ocular cancer in multiple clinical trials, both as monotherapy and in combination with crizotinib. IDEAYA also has a diverse pipeline including IDE849 (a DLL3 antibody drug conjugate for SCLC and neuroendocrine carcinomas), IDE034 (a B7H3/PTK7 bispecific ADC), IDE161 (a PARG inhibitor), IDE705 (a POLQ inhibitor in Phase 1 for BRCA-mutated tumors), IDE397 (a MAT2A inhibitor for MTAP-deleted tumors), IDE892 (a PRMT5 inhibitor), IDE574 (a KAT6/7 inhibitor for various cancers), and IDE275 (a WRN helicase inhibitor). Additionally, the company has preclinical programs and platforms like DECIPHER, INQUIRE, and HARMONY for drug discovery.
Where is IDEAYA Biosciences (IDYA) listed and what currency is used?
IDEAYA Biosciences is listed on the Nasdaq Global Select Market under the ticker symbol IDYA. The trading currency is the US Dollar (USD), reflecting its primary listing in the United States. As a Nasdaq-listed company, it is subject to the exchange's listing requirements and reporting standards. Investors can trade IDYA shares during regular market hours on the Nasdaq exchange.
What sector and industry does IDEAYA Biosciences (IDYA) operate in?
IDEAYA Biosciences operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative therapies for cancer treatment, leveraging molecular diagnostics to identify patient populations that are most likely to benefit from its targeted therapeutics. The biotechnology industry is characterized by high research and development costs, long development timelines, and significant regulatory oversight. IDEAYA's work in precision oncology places it at the forefront of personalized medicine, aiming to improve outcomes for patients with specific genetic mutations or biomarkers.
Where is IDEAYA Biosciences (IDYA) headquartered and what markets does it serve?
IDEAYA Biosciences is headquartered in the United States, as indicated by its country of incorporation. The company primarily serves the US market, focusing on developing and commercializing oncology therapeutics for patients in the United States. While its clinical trials and research activities are based in the US, the company may also engage in global collaborations and strategic alliances, such as its partnership with GlaxoSmithKline (GSK) for the development of IDE705 (GSK101). However, its core operations and target market remain centered in the US, where it seeks to address unmet medical needs in cancer treatment through precision medicine approaches.
What is the business model of IDEAYA Biosciences (IDYA) and how does it generate revenue?
IDEAYA Biosciences operates as a clinical-stage biotechnology company, meaning it has not yet generated revenue from product sales. Its business model focuses on research and development of targeted cancer therapies, with the goal of eventually obtaining regulatory approval and commercializing its drug candidates. The company generates revenue through strategic alliances and collaborations, such as its partnership with GlaxoSmithKline for IDE705 (GSK101), which may include upfront payments, milestone payments, and royalties. IDEAYA also leverages proprietary platforms like DECIPHER (a dual CRISPR library for synthetic lethality target discovery), INQUIRE (a chemical library), and HARMONY (machine-learning engines) to enhance its drug discovery capabilities. Until it achieves commercial sales, the company relies on equity financing, partnerships, and grants to fund its operations.